|
Chemical
Name:
Amoxapine Brand
Name:
Asendin Manufacturer:
Watson
(of generic) Description:
A
tricyclic antidepressant Indications
and Use: For
the relief of symptoms of depression. Contraindications,
Warnings and Precautions:
Do not give
concomitantly or within 14 days of use with monoamine oxidase inhibitors.
Use cautiously in patients with a history of urinary retention,
angle-closure glaucoma, increased intraocular pressure or cardiovascular
disease. Tricyclic drugs, when
given in high doses, have been reported to produce arrhythmias, sinus
tachycardia and prolongation of the conduction time.
Discontinue the drug gradually several days prior to any scheduled
surgery. Do not use with alcohol.
Amoxapine has been associated with neuroleptic malignant syndrome
(NMS), a rare but life-threatening syndrome usually seen with
phenothiazine treatment. Avoid
concomitant use with central nervous system depressants.
Use cautiously with clonidine, epinephrine or norepinephrine because of
an increased hypertensive effect. Amoxapine
may elevate liver function tests, decrease white blood cell counts and change
serum glucose levels. Adverse
Reactions:
Possible common side effects may include dizziness, drowsiness
orthostatic hypotension, tachycardia and dry mouth.
Less common side effects may include constipation, urinary retention,
photosensitivity, nervousness, confusion, hypertension, headache, insomnia, EEG
changes, blurred vision, nausea, sweating and edema. Dosing
Range:
In adults, the initial dose may be 50 mg to 150mg per day.
Doses above 300mg per day are made only if 300mg per day has been
ineffective for at least two weeks. Maximum
recommended dosage for outpatients is 400mg per day. |
|
These pages are solely for public informational purposes. The information cannot be relied on to make diagnoses or prescribe treatment in any individual. Persons who require such services should consult with a licensed professional. Send mail to ropa@redoakpsychiatry.com with questions or comments about this web site.© 2000 Red Oak Psychiatry Associates, P.A. Updated
11/26/2007
|